
Boryung completes in-house production of Alimta, strengthens CDMO ambitions
Boryung said it has completed the in-house production transfer of Alimta (ingredient: pemetrexed), a chemotherapy drug for non-small cell lung cancer (NSCLC). The move marks the culmination of the company’s ongoing Legacy Brands Acquisition (LBA) strategy, …